[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558423":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":35,"responsibleParty":56,"collaborators":59,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":20,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":20,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":84,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ablation-Len-PD-1 inhibitor","EXPERIMENTAL","ablation of oligometastasis therapy combined with lenvatinib and PD-1 inhibitor",[13],"Procedure: ablation of oligometastasis",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","ablation of oligometastasis","The oligometastasis of hepatocellular carcinoma are ablation completely by ablation (including microwave ablation, radiofrequency ablation, and cryoablation)",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Feng Duan, MD","Chinese PLA General Hospital","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Qunfang Zhou, MD","CONTACT","86 19868000115","zhouqun988509@163.com",{"name":23,"role":29,"phone":33,"phoneExt":20,"email":34},"86 13910984586","duanfeng@vip.sina.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Chinese PLA General hospital","RECRUITING","Beijing","None Selected","100853","China","CN",{"type":45,"coordinates":46},"Point",[47,48],116.39723,39.9075,{"lat":48,"lon":47},[51,53],{"name":52,"role":29,"phone":20,"phoneExt":20,"email":31},"Qunfang Zhou",{"name":54,"role":29,"phone":55,"phoneExt":20,"email":34},"Feng Duan","8613910984586",{"type":25,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Zhou Qunfang","Clinical Professor",[60],{"name":24,"class":6},"100558423","ablation-of-oligometastasis-combined-with-lenvatinib-and-pd-1-inhibitor-for-advanced-hepatocellular-carcinoma-100558423",false,"NCT06550921","Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma","Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Multicenter, Prospective, Phase II Study","Inclusion Criteria:\n\n1. diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases 20;\n2. presence of oligometastasis, the metastases found within three month of HCC diagnosis;\n3. metastases with limited five sites and no more two organs involved, with a maximum diameter of ≤5cm;\n4. receipt of Lenvatinib and PD-1 inhibitor as the first-line systemic therapy for a minimum of 3 months before study ablation, with controlled intrahepatic tumors and no progression of metastases. Controlled intrahepatic tumors were defined as those showing a partial or stable response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST);\n5. undergone locoregional treatments, including transarterial artery chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC);\n6. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n7. no history of other malignancies.\n8. life expectancy more than 3 months;\n9. agreed to participated in this clinical trial;\n10. Hemameba ≥3.0 x109\u002FL, neutrophil ≥1.5x109\u002FL, hemoglobin≥10.0 g\u002FL, platelet≥100x 109\u002FL, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml\u002Fmin.\n\nExclusion Criteria:\n\n1. recurrent HCC;\n2. advanced HCC Lenvatinib and PD-1 inhibitor treated with as second systemic therapy;\n3. age \\\u003C 18 years or \\> 75 years;\n4. advanced HCC with more than five metastases;\n5. no response to Lenvatinib;\n6. metastases size \\> 5 cm;\n7. life expectancy less than 3 months.","ALL","18 Years","75 Years",{"count":72,"type":73},60,"ESTIMATED","INTERVENTIONAL",[76],"NA","Ablation has been an effective approach for treating intrathoracic metastases. However, for hepatocellular carcinoma with oligometastasis, ablation of metastases remains relatively unexplored.",[79,80,81,82,83],"Advanced Hepatocellular Carcinoma","Oligometastasis","Ablation","Anti-PD1 Antibody","Lenvatinib",[85,86,87,88],"Lenvatinb","Tislelizumab","Sintilimab","Camrelizumab","2024-08-08",{"date":91,"type":92},"2024-08-13","ACTUAL",{"date":94,"type":92},"2024-08-01",{"date":96,"type":73},"2027-08-30",{"name":5,"class":6},1]